CN104245699B - Nedd8‑活化酶抑制剂和低甲基化剂的投与 - Google Patents
Nedd8‑活化酶抑制剂和低甲基化剂的投与 Download PDFInfo
- Publication number
- CN104245699B CN104245699B CN201280062112.9A CN201280062112A CN104245699B CN 104245699 B CN104245699 B CN 104245699B CN 201280062112 A CN201280062112 A CN 201280062112A CN 104245699 B CN104245699 B CN 104245699B
- Authority
- CN
- China
- Prior art keywords
- acceptable salt
- pharmaceutically acceptable
- purposes according
- azacitidine
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *C1C(O)=C(CO)O[C@]1N1C=*C(N)=[N+]C1 Chemical compound *C1C(O)=C(CO)O[C@]1N1C=*C(N)=[N+]C1 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161555049P | 2011-11-03 | 2011-11-03 | |
| US61/555,049 | 2011-11-03 | ||
| PCT/US2012/063382 WO2013067396A2 (en) | 2011-11-03 | 2012-11-02 | Administration of nedd8-activating enzyme inhibitor and hypomethylating agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104245699A CN104245699A (zh) | 2014-12-24 |
| CN104245699B true CN104245699B (zh) | 2017-06-27 |
Family
ID=48193039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280062112.9A Active CN104245699B (zh) | 2011-11-03 | 2012-11-02 | Nedd8‑活化酶抑制剂和低甲基化剂的投与 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8980850B2 (enExample) |
| EP (1) | EP2773360B1 (enExample) |
| JP (2) | JP6231988B2 (enExample) |
| KR (1) | KR101987861B1 (enExample) |
| CN (1) | CN104245699B (enExample) |
| AU (1) | AU2012321106C1 (enExample) |
| BR (1) | BR112014010699B1 (enExample) |
| CA (1) | CA2854461C (enExample) |
| EA (1) | EA028380B1 (enExample) |
| ES (1) | ES2668272T3 (enExample) |
| GE (1) | GEP20196940B (enExample) |
| HK (1) | HK1201733A1 (enExample) |
| IL (1) | IL232353B (enExample) |
| MA (1) | MA35662B1 (enExample) |
| MX (1) | MX357835B (enExample) |
| MY (1) | MY176125A (enExample) |
| PH (1) | PH12014501001B1 (enExample) |
| PL (1) | PL2773360T3 (enExample) |
| SG (1) | SG11201401895WA (enExample) |
| TN (1) | TN2014000194A1 (enExample) |
| TR (1) | TR201807342T4 (enExample) |
| UA (1) | UA114414C2 (enExample) |
| WO (1) | WO2013067396A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2562245C2 (ru) | 2009-05-14 | 2015-09-10 | Милленниум Фармасьютикалз, Инк. | ГИДРОХЛОРИД (1S,2S,4R)-4-{ 4-[(1S)-2,3-ДИГИДРО-1Н-ИНДЕН-1-ИЛАМИНО]-7Н-ПИРРОЛО [2,3-d]ПИРИМИДИН-7-ИЛ} -2-ГИДРОКСИЦИКЛОПЕНТИЛ)МЕТИЛ СУЛЬФАМАТА |
| HK1199252A1 (en) * | 2011-08-24 | 2015-06-26 | Millennium Pharmaceuticals, Inc. | Inhibitors of nedd8-activating enzyme |
| EP2764866A1 (en) * | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
| WO2014186388A2 (en) | 2013-05-14 | 2014-11-20 | Millennium Pharmaceutcals, Inc. | Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents |
| WO2015011235A1 (en) * | 2013-07-26 | 2015-01-29 | Boehringer Ingelheim International Gmbh | Volasertib in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome ii |
| SG11201608303QA (en) | 2014-04-04 | 2016-11-29 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| CN103948590A (zh) * | 2014-05-22 | 2014-07-30 | 中国药科大学 | Nedd8激活酶抑制剂及其医药用途 |
| EP3362070B1 (en) * | 2015-10-15 | 2021-01-27 | Celgene Corporation | Combination of a mutant isocitrate dehydrogenase 2 inhibitor with azacitidine and its use for treating acute myelogenous leukemia |
| WO2018218119A1 (en) * | 2017-05-25 | 2018-11-29 | The Board Of Trustees Of The Leland Stanford Junior University | Combination of low dose il-2 and an inhibitor of treg il-2r desensitization to treat autoimmune and allergic inflammatory diseases |
| JP2020534331A (ja) * | 2017-09-21 | 2020-11-26 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | （（１ｓ，２ｓ，４ｒ）−４−｛４−［（１ｓ）−２，３−ジヒドロ−１ｈ−インデン−１−イルアミノ］−７ｈ−ピロロ［２，３−ｄ］ピリミジン−７−イル｝−２−ヒドロキシシクロペンチル）メチルスルファメートの共結晶形態、その製剤及び使用 |
| US20220017908A1 (en) * | 2018-11-20 | 2022-01-20 | Fulcrum Therapeutics, Inc. | Compositions and methods for increasing fetal hemoglobin and treating sickle cell disease |
| EP3938050A1 (en) | 2019-03-15 | 2022-01-19 | Fulcrum Therapeutics, Inc. | Macrocyclic azolopyridine derivatives as eed and prc2 modulators |
| WO2023025668A1 (en) | 2021-08-25 | 2023-03-02 | Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune | Methods for the generation of stem cell memory t cells for adoptive t cell therapy |
| WO2023242235A1 (en) * | 2022-06-14 | 2023-12-21 | Scandion Oncology A/S | Abcg2 inhibitor and nae inhibitor for the treatment of cancer |
| CN115007323B (zh) * | 2022-06-17 | 2024-01-23 | 中南大学 | 一种抑制矿物中黄铁矿浮选的方法 |
| EP4554608A1 (en) * | 2022-07-11 | 2025-05-21 | Westlake University | Use of a fbxo42 specific inhibitor in treating notch signaling-dependent disease |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101516850A (zh) * | 2006-08-08 | 2009-08-26 | 米伦纽姆医药公司 | 适用作e1活化酶抑制剂的杂芳基化合物 |
| US20100292177A1 (en) * | 2009-03-23 | 2010-11-18 | Armstrong Robert C | Methods of treatment using combination therapy |
| CN102088969A (zh) * | 2008-06-09 | 2011-06-08 | 西克拉塞尔有限公司 | 沙帕他滨或cndac与dna甲基转移酶抑制剂如地西他滨和普鲁卡因的组合 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6887855B2 (en) | 2003-03-17 | 2005-05-03 | Pharmion Corporation | Forms of 5-azacytidine |
| US6943249B2 (en) | 2003-03-17 | 2005-09-13 | Ash Stevens, Inc. | Methods for isolating crystalline Form I of 5-azacytidine |
| US20060063735A1 (en) | 2004-09-17 | 2006-03-23 | Supergen, Inc. | Salts of 5-azacytidine |
| US20060128654A1 (en) | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of cytidine analogs and derivatives |
| WO2006084281A1 (en) | 2005-02-04 | 2006-08-10 | Millennium Pharmaceuticals, Inc. | Inhibitors of e1 activating enzymes |
| JP5231251B2 (ja) | 2006-02-02 | 2013-07-10 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | Ｅ１活性化酵素の阻害剤 |
| WO2008028193A2 (en) | 2006-09-01 | 2008-03-06 | Pharmion Corporation | Colon-targeted oral formulations of cytidine analogs |
| WO2009058394A1 (en) | 2007-11-01 | 2009-05-07 | Celgene Corporation | Cytidine analogs for treatment of myelodysplastic syndromes |
| WO2009106549A2 (en) * | 2008-02-26 | 2009-09-03 | Nerviano Medical Sciences S.R.L. | Antitumor combination comprising a morpholinyl anthracycline derivative and demethylating agents |
| SI2695609T1 (sl) | 2008-05-15 | 2020-03-31 | Celgene Corporation | Oral formulacije anologov citidina in postopki za njihovo uporabo |
| RU2562245C2 (ru) | 2009-05-14 | 2015-09-10 | Милленниум Фармасьютикалз, Инк. | ГИДРОХЛОРИД (1S,2S,4R)-4-{ 4-[(1S)-2,3-ДИГИДРО-1Н-ИНДЕН-1-ИЛАМИНО]-7Н-ПИРРОЛО [2,3-d]ПИРИМИДИН-7-ИЛ} -2-ГИДРОКСИЦИКЛОПЕНТИЛ)МЕТИЛ СУЛЬФАМАТА |
| EP2670396A1 (en) | 2011-01-31 | 2013-12-11 | Celgene Corporation | Pharmaceutical compositions of cytidine analogs and methods of use thereof |
| EP2773322A1 (en) | 2011-11-01 | 2014-09-10 | Celgene Corporation | Methods for treating cancers using oral formulations of cytidine analogs |
-
2012
- 2012-11-02 EP EP12844799.2A patent/EP2773360B1/en active Active
- 2012-11-02 WO PCT/US2012/063382 patent/WO2013067396A2/en not_active Ceased
- 2012-11-02 HK HK15102294.2A patent/HK1201733A1/xx unknown
- 2012-11-02 KR KR1020147014236A patent/KR101987861B1/ko not_active Expired - Fee Related
- 2012-11-02 CN CN201280062112.9A patent/CN104245699B/zh active Active
- 2012-11-02 PL PL12844799T patent/PL2773360T3/pl unknown
- 2012-11-02 GE GEAP201213483A patent/GEP20196940B/en unknown
- 2012-11-02 BR BR112014010699-1A patent/BR112014010699B1/pt not_active IP Right Cessation
- 2012-11-02 UA UAA201405842A patent/UA114414C2/uk unknown
- 2012-11-02 EA EA201400539A patent/EA028380B1/ru not_active IP Right Cessation
- 2012-11-02 AU AU2012321106A patent/AU2012321106C1/en not_active Ceased
- 2012-11-02 ES ES12844799.2T patent/ES2668272T3/es active Active
- 2012-11-02 MX MX2014005323A patent/MX357835B/es active IP Right Grant
- 2012-11-02 MY MYPI2014001239A patent/MY176125A/en unknown
- 2012-11-02 PH PH1/2014/501001A patent/PH12014501001B1/en unknown
- 2012-11-02 CA CA2854461A patent/CA2854461C/en not_active Expired - Fee Related
- 2012-11-02 US US13/667,641 patent/US8980850B2/en active Active
- 2012-11-02 SG SG11201401895WA patent/SG11201401895WA/en unknown
- 2012-11-02 TR TR2018/07342T patent/TR201807342T4/tr unknown
- 2012-11-02 JP JP2014540146A patent/JP6231988B2/ja active Active
-
2014
- 2014-04-29 IL IL232353A patent/IL232353B/en active IP Right Grant
- 2014-04-30 TN TNP2014000194A patent/TN2014000194A1/en unknown
- 2014-05-26 MA MA37066A patent/MA35662B1/fr unknown
-
2015
- 2015-01-23 US US14/603,717 patent/US20150366886A1/en not_active Abandoned
-
2017
- 2017-10-20 JP JP2017203560A patent/JP2018009035A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101516850A (zh) * | 2006-08-08 | 2009-08-26 | 米伦纽姆医药公司 | 适用作e1活化酶抑制剂的杂芳基化合物 |
| CN102088969A (zh) * | 2008-06-09 | 2011-06-08 | 西克拉塞尔有限公司 | 沙帕他滨或cndac与dna甲基转移酶抑制剂如地西他滨和普鲁卡因的组合 |
| US20100292177A1 (en) * | 2009-03-23 | 2010-11-18 | Armstrong Robert C | Methods of treatment using combination therapy |
Non-Patent Citations (2)
| Title |
|---|
| "Substrate-Assisted Inhibition of Ubiquitin-like Protein-Activating Enzymes: The NEDD8 E1 Inhibitor MLN4924 Forms a NEDD8-AMP Mimetic In Situ";James E. Brownell et al.;《Molecular Cell》;20100115;第37卷;第102-111页 * |
| "Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer";Meng Wang et al.;《Expert Opin. Ther. Targets》;20110331;第15卷(第3期);第253-264页 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104245699B (zh) | Nedd8‑活化酶抑制剂和低甲基化剂的投与 | |
| CN104428001A (zh) | Raf抑制剂和mek抑制剂在黑素瘤治疗中的投与 | |
| US20160129003A1 (en) | Pharmaceutical Combinations | |
| KR20160135230A (ko) | 암의 치료를 위한 병용 요법으로서의 에리불린 및 mTOR 억제제의 용도 | |
| JP2013541587A (ja) | Ｎｅｄｄ８活性化酵素阻害剤の投与 | |
| US10786505B2 (en) | Administration of NEDD8-activating enzyme inhibitor and chemotherapeutic agents | |
| US20250064824A1 (en) | Administration of aurora kinase inhibitor and chemotherapeutic agents | |
| TW201315471A (zh) | 使用ＰＩ３Ｋβ抑制劑及包括ＭＥＫ及ＲＡＦ抑制劑之ＭＡＰＫ通道抑制劑之供治療癌症之組合物及方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20211025 Address after: Osaka, Japan Patentee after: TAKEDA PHARMACEUTICAL Co.,Ltd. Address before: Massachusetts, USA Patentee before: MILLENNIUM PHARMACEUTICALS, Inc. |